• Oxaliplatin: Workflow Advances for Platinum-Based Chemothera

  2026-07-23

  Explore how Oxaliplatin empowers next-generation tumor models and personalized drug screening. This guide details proven protocols, troubleshooting insights, and the latest innovations in leveraging platinum-based chemotherapeutic agents for more predictive and robust cancer research.

• Valemetostat (DS-3201): Advanced Workflows in EZH2 Mutant Ly

  2026-07-23

  Valemetostat (DS-3201) enables precise, high-sensitivity epigenetic modulation for lymphoma research, particularly in EZH2-mutant and relapsed/refractory follicular lymphoma models. This article details stepwise protocol optimizations, troubleshooting strategies, and new insights from recent breakthrough studies, empowering researchers to maximize reproducibility and translational impact.

• Enhancing Proteotoxic Cell Death in Prostate Cancer via Dual

  2026-07-22

  This study reveals that combining the cyclophilin inhibitor rencofilstat with the proteasome inhibitor ixazomib selectively intensifies proteotoxic and apoptotic cell death in advanced prostate cancer cells while sparing non-cancerous cells. The mechanistic insights into unfolded protein response modulation offer new avenues for targeting resistant prostate malignancies.

• TMEM16F in Kupffer Cells Protects Against Listeria-Induced L

  2026-07-22

  This study identifies TMEM16F, a calcium-activated lipid scramblase, as a critical regulator of liver inflammation and metabolic homeostasis in response to Listeria monocytogenes infection. The research demonstrates that TMEM16F expression in liver-resident Kupffer cells, rather than in lymphocytes, is essential for cell membrane repair, limiting necroptotic cell death and subsequent tissue injury.

• RapaLink-1: Redefining mTORC1 Inhibition for Dormancy and On

  2026-07-21

  Discover how RapaLink-1, a third-generation mTOR inhibitor, enables robust mTORC1 inhibition and outperforms previous inhibitors in cancer and embryonic dormancy models. This article delivers advanced insights, mechanistic depth, and practical assay guidance beyond standard protocol reviews.

• Redefining In Vivo Imaging: Cy5.5 NHS Ester in Translational

  2026-07-21

  Explore the mechanistic edge and translational impact of Cy5.5 NHS ester (non-sulfonated), a near-infrared fluorescent dye that is transforming biomolecule labeling and in vivo imaging. This article delivers strategic guidance for researchers bridging molecular workflow design and preclinical innovation, integrating evidence from recent polysaccharide absorption studies and deep-tissue imaging advances.

• RNA Pol II Degradation Triggers Active Apoptosis in Cancer C

  2026-07-20

  Harper et al. (2025) demonstrate that cell death following RNA Pol II inhibition is not simply due to loss of transcription, but is actively signaled through the loss of hypophosphorylated RNA Pol IIA, linking nuclear events to mitochondrial apoptosis. This mechanistic insight refines our understanding of how transcriptional inhibitors exert cytotoxicity, with direct implications for cancer biology and epigenetic modulation research.

• Applied Use-Cases for the γH2AX DNA Damage Detection Kit

  2026-07-20

  Harnessing the γH2AX DNA Damage Detection Kit (Mouse mAb/Red) elevates DNA double-strand break research with sensitive, quantitative immunofluorescence. This article delivers protocol enhancements, troubleshooting insights, and translational workflows, drawing from recent advances in nanomedicine and precision radiotherapy.

• AZD8055: Technical Guidance for mTOR Inhibition Workflows

  2026-07-19

  AZD8055 is a potent, selective mTOR inhibitor suitable for dissecting mTORC1 and mTORC2 signaling in preclinical cancer and metabolic research models. It should not be used for studies requiring clinical efficacy endpoints or protocols demanding water solubility. This article provides actionable protocol parameters and workflow best practices for researchers using AZD8055.

• Sodium Orthovanadate: Precision Tools for PI-3K/AKT Pathway

  2026-07-18

  Explore how Sodium Orthovanadate (Na3VO4) enables precise control over phosphorylation state preservation and advanced PI-3K/AKT pathway studies. This article offers unique insights into assay optimization, inhibitor mechanisms, and experimental best practices.

• Belinostat (PXD101): Advancing Translational Epigenetic Onco

  2026-07-17

  This thought-leadership article explores how Belinostat (PXD101), a potent pan-HDAC inhibitor from APExBIO, is redefining the strategic landscape for translational cancer researchers. Blending mechanistic insights with actionable guidance, we connect in vitro findings, protocol best practices, and real-world challenges in drug response evaluation, while highlighting both current achievements and the visionary horizons of epigenetic cancer therapy.

• Nicotinamide Riboside Chloride (NIAGEN): Enabling High-Fidel

  2026-07-17

  Explore how Nicotinamide Riboside Chloride (NIAGEN) empowers next-generation neurodegenerative disease research by optimizing NAD+ metabolism, supporting robust stem cell-derived retinal ganglion cell workflows, and advancing metabolic dysfunction modeling. This article uniquely unpacks assay design and translational considerations, grounded in recent methodological breakthroughs.

• Targeted Demethylation Reactivates BRD7 in Nasopharyngeal Ca

  2026-07-16

  This study establishes that BRD7 promoter hypermethylation is a key driver of its silencing in nasopharyngeal carcinoma (NPC). By applying a CRISPR/dCas9-TET1CD demethylation system, the authors demonstrate robust BRD7 reactivation and suppression of tumor progression, highlighting a precise epigenetic therapeutic strategy.

• Dissecting Drug Responses: Improved In Vitro Metrics for Can

  2026-07-16

  Schwartz’s dissertation introduces a rigorous framework for evaluating anti-cancer drug responses by distinguishing growth inhibition from cell death using optimized in vitro methods. This dual-metric approach clarifies the mechanistic impact of compounds like HDAC inhibitors, offering researchers more actionable insights for cancer drug discovery and resistance studies.

• EZH2 Inhibitors in HPV-Linked Cervical Cancer: Efficacy and

  2026-07-15

  The referenced study demonstrates that selective EZH2 inhibitors, notably EPZ-6438, effectively suppress proliferation and induce apoptosis in both HPV-positive and HPV-negative cervical cancer cells by downregulating oncogenic and epigenetic drivers. These findings position EZH2 inhibition as a promising strategy for targeting HPV-associated cervical malignancies with potentially reduced toxicity compared to cisplatin.

15852 records 1/1057 page Next 12345 下5页 Last page